US biotech criticises govt panel recommendations on limiting gene patents
This article was originally published in RAJ Devices
Executive Summary
A new report by a US government advisory panel recommending major changes to the current patent policy and licensing practices for genetic tests has been criticised by the biotech industry and other stakeholders who say it would “seriously hamper” public-private collaborations and the commercialisation of publicly funded research1-3.